First authorJournal abbreviation yearCountrySourceHPV primersNo. casesAny61116183133354556
Europe
    Perez-Ayala MInt J Cancer 1990SpainFFTS-PCR only4854.20.054.2
    Salam MEur J Surg Oncol 1995United KingdomPE*MY09/113622.28.32.85.60.00.0
    Snijders PJInt J Cancer 1996NetherlandsFF and PE*GP5/63119.40.00.019.40.00.00.0
    Lie ESActa Otolaryngol 1996NorwayFF*MY09/11 CP1l/CPIIG GP5+/6+397.72.60.00.00.00.0
    Fouret PArch Otolaryngol Head Neck Surg 1997FrancePEWD72/76+WD66/67/1541036.86.80.00.00.00.0
    Alvarez AIAm J Otolaryngol 1997SpainUnsure*TS-PCR only3525.722.95.70.0
    Poljak MActa Otolaryngol Suppl 1997SloveniaPE*MY09/11 GP5/6 WD72/76+WD66/67/154303.30.00.03.30.00.0
    Cattani PClin Cancer Res 1998ItalyFF*MY09/117529.30.00.012.010.70.01.3
    Hoffman MActa Otolaryngol 1998GermanyFF*MY09/11 of TS-PCR negative5121.60.00.03.92.00.00.0
    Andl TCancer Res 1998GermanyFF*WD72/76+WD66/67/1543026.70.00.026.70.00.0
    Adams VAnticancer Res 1999SwitzerlandFF*MY09/113619.40.00.019.40.00.00.00.00.00.0
    Lindelberg HCancer Lett 1999DenmarkUnsure*MY09/11 GP5+/6+ CPI/CPII303.30.00.00.00.00.0
    Gorgoulis VGHum Pathol 1999GreecePEMY09/11 GP5/69120.93.30.014.33.30.03.30.0
    Badaracco GAnticancer Res 2000ItalyFF*MY09/11 HPV6 and 16 E6/E22250.018.20.027.30.00.00.00.04.50.0
    Kleist BJ Oral Pathol Med 2000GermanyPE*MY09/113520.011.45.7
    Mork JNEJM 2001Norway, Finland, SwedenPE*GP5+/6+ CpI/CpIIG4012.50.00.02.50.00.0
    Klussman JPCancer 2001GermanyUnsure*A10/A5-A6/A83016.70.00.013.30.00.00.00.00.00.0
    van Houten VMInt J Cancer 2001NetherlandsFFGP5+/6+90.00.00.00.00.00.00.00.0
    Koskinen WJInt J Cancer 2003FinlandFFSPF10 FAP 59/64 CP65/70 CP66/692850.010.73.642.90.00.014.30.00.00.0
North America
    Brandwein MSAnn Otol Rhinol Laryngol 1993United StatesPEBauer L1 consensus primers407.50.00.02.50.00.00.00.00.0
    Fliss DMLaryngoscope 1994CanadaPE*TS-PCR only2944.831.031.0
    Shen JMod Pathol 1996United StatesPE*MY09/11329.43.13.10.03.1
    Paz IBCancer 1997United StatesFFMY09/11 IU/IUDO567.10.05.40.0
    Gillison MLJ Natl Cancer Inst 2000United StatesFF*PGMY09/1110314.60.00.014.60.01.00.00.00.00.0
    Smith EMAnn Otol Rhinol Laryngol 2000United StatesFF and PEMY09/11238.70.00.04.30.04.30.00.00.00.0
    Ringstrom EClin Cancer Res 2002United StatesFF*MY09/11147.17.10.0
Asia
    Ogura HJpn J Cancer Res 1991JapanUnsureTS-PCR only2810.710.73.6
    Shidara KLaryngoscope 1994JapanPEL1C1/L1C24524.40.00.020.04.40.00.00.00.00.0
    Suzuki TJpn J Cancer Res 1994JapanPEL1C1/L1C24126.80.00.022.04.90.00.0
    Ma XLJ Med Virol 1998JapanPEpU-1M/pU-2R10258.824.52.029.421.61.0
    Mineta HAnticancer Res 1998JapanFFTS-PCR only4231.026.24.8
    Tsuhako KJ Oral Pathol Med 2000JapanPE*TS-PCR only21001000.01000.0
    Jacob SEJ Surg Oncol 2002IndiaPETS-PCR only4434.10.00.034.10.0
    Higa MOral Oncol 2003JapanFF*TS-PCR only21001000.01000.0
Other (includes Central and South America, Australia, and Africa)
    Garcia-Milian RActa Otolaryngol 1998CubaFF*MY09/113348.53.00.045.53.0
  • * Study assessed a human gene marker for the quality of the cancer specimen and reported results for this laboratory assessment.

  • Author provided additional data from their study for this review.